全文获取类型
收费全文 | 143篇 |
免费 | 30篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 3篇 |
基础医学 | 28篇 |
口腔科学 | 2篇 |
临床医学 | 8篇 |
内科学 | 38篇 |
皮肤病学 | 1篇 |
神经病学 | 23篇 |
特种医学 | 1篇 |
外科学 | 17篇 |
预防医学 | 21篇 |
眼科学 | 1篇 |
药学 | 11篇 |
中国医学 | 1篇 |
肿瘤学 | 14篇 |
出版年
2024年 | 1篇 |
2023年 | 9篇 |
2022年 | 2篇 |
2021年 | 12篇 |
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 13篇 |
2017年 | 14篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 13篇 |
2013年 | 13篇 |
2012年 | 12篇 |
2011年 | 19篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 5篇 |
2006年 | 5篇 |
2005年 | 4篇 |
2003年 | 1篇 |
2001年 | 1篇 |
2000年 | 1篇 |
排序方式: 共有173条查询结果,搜索用时 15 毫秒
61.
Barton A Thomson W Ke X Eyre S Hinks A Bowes J Gibbons L Plant D;Wellcome Trust Case Control Consortium Wilson AG Marinou I Morgan A Emery P;YEAR consortium Steer S Hocking L Reid DM Wordsworth P Harrison P Worthington J 《Human molecular genetics》2008,17(15):2274-2279
Rheumatoid arthritis (RA) is an archetypal, common, complex autoimmune disease with both genetic and environmental contributions to disease aetiology. Two novel RA susceptibility loci have been reported from recent genome-wide and candidate gene association studies. We, therefore, investigated the evidence for association of the STAT4 and TRAF1/C5 loci with RA using imputed data from the Wellcome Trust Case Control Consortium (WTCCC). No evidence for association of variants mapping to the TRAF1/C5 gene was detected in the 1860 RA cases and 2930 control samples tested in that study. Variants mapping to the STAT4 gene did show evidence for association (rs7574865, P = 0.04). Given the association of the TRAF1/C5 locus in two previous large case-control series from populations of European descent and the evidence for association of the STAT4 locus in the WTCCC study, single nucleotide polymorphisms mapping to these loci were tested for association with RA in an independent UK series comprising DNA from >3000 cases with disease and >3000 controls and a combined analysis including the WTCCC data was undertaken. We confirm association of the STAT4 and the TRAF1/C5 loci with RA bringing to 5 the number of confirmed susceptibility loci. The effect sizes are less than those reported previously but are likely to be a more accurate reflection of the true effect size given the larger size of the cohort investigated in the current study. 相似文献
62.
A. C. Shore H. M. Colhoun A. Natali C. Palombo G. Östling K. Aizawa C. Kennbäck F. Casanova M. Persson K. Gooding P. E. Gates F. Khan H. C. Looker F. Adams J. Belch S. Pinnoli E. Venturi C. Morizzo I. Goncalves C. Ladenvall J. Nilsson the SUMMIT consortium 《Journal of internal medicine》2015,278(3):291-302
63.
Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study
下载免费PDF全文
![点击此处可从《International journal of rheumatic diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
64.
Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation‐05 Study
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
R. C. Starling J. Stehlik D. A. Baran B. Armstrong J. R. Stone D. Ikle Y. Morrison N. D. Bridges P. Putheti T. B. Strom M. Bhasin I. Guleria A. Chandraker M. Sayegh K. P. Daly D. M. Briscoe P. S. Heeger the CTOT‐ consortium 《American journal of transplantation》2016,16(1):121-136
Identification of biomarkers that assess posttransplant risk is needed to improve long‐term outcomes following heart transplantation. The Clinical Trials in Organ Transplantation (CTOT)‐05 protocol was an observational, multicenter, cohort study of 200 heart transplant recipients followed for the first posttransplant year. The primary endpoint was a composite of death, graft loss/retransplantation, biopsy‐proven acute rejection (BPAR), and cardiac allograft vasculopathy (CAV) as defined by intravascular ultrasound (IVUS). We serially measured anti‐HLA‐ and auto‐antibodies, angiogenic proteins, peripheral blood allo‐reactivity, and peripheral blood gene expression patterns. We correlated assay results and clinical characteristics with the composite endpoint and its components. The composite endpoint was associated with older donor allografts (p < 0.03) and with recipient anti‐HLA antibody (p < 0.04). Recipient CMV‐negativity (regardless of donor status) was associated with BPAR (p < 0.001), and increases in plasma vascular endothelial growth factor‐C (OR 20; 95%CI:1.9–218) combined with decreases in endothelin‐1 (OR 0.14; 95%CI:0.02–0.97) associated with CAV. The remaining biomarkers showed no relationships with the study endpoints. While suboptimal endpoint definitions and lower than anticipated event rates were identified as potential study limitations, the results of this multicenter study do not yet support routine use of the selected assays as noninvasive approaches to detect BPAR and/or CAV following heart transplantation. 相似文献
65.
Sohaib Ashraf Shoaib Ashraf Moneeb Ashraf Muhammad Ahmad Imran Larab Kalsoom Uzma N. Siddiqui Iqra Farooq Rutaba Akmal Muhammad Kiwan Akram Sidra Ashraf Muhammad Ghufran Nighat Majeed Zaighum Habib Sundas Rafique Zain-ul -Abdin Shahroze Arshad Muhammad Sarmad Shahab Sohail Ahmad Hui Zheng Ali Rafique Mirza Sibgha Zulfiqar Muhamad Imran Anwar Ayesha Humayun Talha Mahmud Qazi Abdul Saboor Ali Ahmad Muhammad Ashraf Mateen Izhar DOCTORS LOUNGE consortium 《Phytotherapy research : PTR》2023,37(2):627-644
Until now, no specific and effective treatment exists for coronavirus disease 2019 (COVID-19). Since honey and Nigella sativa (HNS) have established antiviral, antibacterial, antiinflammatory, antioxidant, and immunomodulatory properties, we tested their efficacy for this disease in a multicenter, placebo-controlled, and randomized clinical trial at four medical care facilities in Pakistan. RT-PCR confirmed COVID-19 adults showing moderate or severe disease were enrolled in the trial. Patients were randomly assigned in a 1:1 ratio to receive either honey (1 g kg−1 day−1) and Nigella sativa seeds (80 mg kg−1 day−1) or a placebo for up to 13 days along with standard care. The outcomes included symptoms' alleviation, viral clearance, and 30-day mortality in the intention-to-treat population. Three hundred and thirteen patients, 210 with moderate and 103 with severe disease, underwent randomization from April 30 to July 29, 2020. Among the moderate cases, 107 were assigned to HNS, whereas 103 were assigned to the placebo group. Among the severe cases, 50 were given HNS, and 53 were given the placebo. HNS resulted in ~50% reduction in time taken to alleviate symptoms as compared to placebo (moderate cases: 4 vs. 7 days, Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23–8.84, p < 0.0001 and for severe cases: 6 vs. 13 days, HR: 4.04; 95% CI: 2.46–6.64; p < 0.0001). HNS also cleared the virus earlier than placebo in both moderate cases (6 vs. 10 days, HR: 5.53; 95% CI: 3.76–8.14, p < 0.0001) and severe cases (8.5 vs. 12 days, HR: 4.32; 95% CI: 2.62–7.13, p < 0.0001). HNS further led to a better clinical score on day 6 with normal activity resumption in 63.6% vs. 10.9% among moderate cases (OR: 0.07; 95% CI: 0.03–0.13, p < 0.0001) and hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI: 0.01–0.09, p < 0.0001). In severe cases, the mortality rate was less than 1/4th in the HNS group than in placebo (4% vs. 18.87%, OR: 0.18; 95% CI: 0.02–0.92, p = 0.029). No HNS-related adverse effects were observed. HNS, compared with placebo, significantly improved symptoms, expedited viral load clearance, and reduced mortality in COVID-19 patients. This trial was registered on April 15, 2020 with ClinicalTrials.gov Identifier: NCT04347382. 相似文献
66.
Steef Redeker Emma K. Massey Charlotte Boonstra Jan J. van Busschbach Reinier Timman Harald F. H. Brulez Daan A. A. M. J. Hollander Luuk B. Hilbrands Frederike Bemelman Stefan P. Berger Jacqueline van de Wetering René M. A. van den Dorpel Margriet Dekker-Jansen Willem Weimar Sohal Y. Ismail the Kidney Team at Home consortium 《Transplant international》2021,34(11):2317-2328
Research has shown that a home-based educational intervention for patients with chronic kidney disease results in better knowledge and communication, and more living donor kidney transplantations (LDKT). Implementation research in the field of renal care is almost nonexistent. The aims of this study were (1) to demonstrate generalizability, (2) evaluate the implementation process, and (3) to assess the relationship of intervention effects on LDKT-activity. Eight hospitals participated in the project. Patients eligible for all kidney replacement therapies (KRT) were invited to participate. Effect outcomes were KRT-knowledge and KRT-communication, and treatment choice. Feasibility, fidelity, and intervention costs were assessed as part of the process evaluation. Three hundred and thirty-two patients completed the intervention. There was a significant increase in KRT-knowledge and KRT-communication among participants. One hundred and twenty-nine out of 332 patients (39%) had LDKT-activity, which was in line with the results of the clinical trials. Protocol adherence, knowledge, and age were correlated with LDKT-activity. This unique implementation study shows that the results in practice are comparable to the previous trials, and show that the intervention can be implemented, while maintaining quality. Results from the project resulted in the uptake of the intervention in standard care. We urge other countries to investigate the uptake of the intervention. 相似文献
67.
Ryan M. Surmaitis Marna Rayl Greenberg Natalie E. Ebeling-Koning Phillip M. Grenz Cody R. McWhirter Beth A. Careyva Judith N. Sabino Matthew D. Cook Robert D. Cannon Andrew L. Koons Kenneth D. Katz Hope Kincaid Lexis T. Laubach Gillian A. Beauchamp On behalf of the toxicology investigators consortium 《Journal of medical toxicology》2021,17(1):16
68.
Silvia Polidoro John Gulliver Claudia Galassi Andrea Ranzi Vittorio Krogh Sara Grioni Claudia Agnoli Carlotta Sacerdote Salvatore Panico Ming‐Yi Tsai Nicole Probst‐Hensch Gerard Hoek Zdenko Herceg Roel Vermeulen Alessio Naccarati for the EXPOsOMICS consortium‡ 《Environmental and molecular mutagenesis》2018,59(3):234-246
Air pollution is associated with a broad range of adverse health effects, including mortality and morbidity due to cardio‐ and cerebrovascular diseases (CCVD), but the molecular mechanisms involved are not entirely understood. This study aims to investigate the involvement of oxidative stress and inflammation in the causal chain, and to identify intermediate biomarkers that are associated retrospectively with the exposure and prospectively with the disease. We designed a case‐control study on CCVD nested in a cohort of 18,982 individuals from the EPIC‐Italy study. We measured air pollution, inflammatory biomarkers, and whole‐genome DNA methylation in blood collected up to 17 years before the diagnosis. The study sample includes all the incident CCVD cases among former‐ and never‐smokers, with available stored blood sample, that arose in the cohort during the follow‐up. We identified enrichment of altered DNA methylation in “ROS/Glutathione/Cytotoxic granules” and “Cytokine signaling” pathways related genes, associated with both air pollution (multiple comparisons adjusted p for enrichment ranging from 0.01 to 0.03 depending on pollutant) and with CCVD risk (P = 0.04 and P = 0.03, respectively). Also, Interleukin‐17 was associated with higher exposure to NO2 (P = 0.0004), NOx (P = 0.0005), and CCVD risk (OR = 1.79; CI 1.04–3.11; P = 0.04 comparing extreme tertiles). Our findings indicate that chronic exposure to air pollution can lead to oxidative stress, which in turn activates a cascade of inflammatory responses mainly involving the “Cytokine signaling” pathway, leading to increased risk of CCVD. Inflammatory proteins and DNA methylation alterations can be detected several years before CCVD diagnosis in blood samples, being promising preclinical biomarkers. Environ. Mol. Mutagen. 59:234–246, 2018. © 2017 Wiley Periodicals, Inc. 相似文献
69.
Bode A Caroli A Huberts W Planken N Antiga L Bosboom M Remuzzi A Tordoir J;ARCH project consortium 《The journal of vascular access》2011,12(4):369-376
Despite clinical guidelines and the possibility of diagnostic vascular imaging, creation and maintenance of a vascular access (VA) remains problematic: avoiding short- and long-term VA dysfunction is challenging. Although prognostic factors for VA dysfunction have been identified in previous studies, their potential interplay at a systemic level is disregarded. Consideration of multiple prognostic patient specific factors and their complex interaction using dedicated computational modeling tools might improve outcome after VA creation by enabling a better selection of VA configuration. These computational modeling tools are developed and validated in the ARCH project: a joint initiative of four medical centers and three industrial partners (FP7-ICT-224390). This paper reports the rationale behind computational modeling and presents the clinical study protocol designed for calibrating and validating these modeling tools. The clinical study is based on the pre-operative collection of structural and functional data at a vascular level, as well as a VA functional evaluation during the follow-up period. The strategy adopted to perform the study and for data collection is also described here. 相似文献
70.
Susanne Fischer Guido Miccinesi Rainer Hornung Georg Bosshard Luc Deliens Agnes van der Heide Tore Nilstun Michael Norup Bregje D. Onwuteaka-Philipsen On behalf of the EURELD consortium 《Sozial- und Pr?ventivmedizin》2006,6(3):24-33
Objectives: To determine the direction and magnitude of participation bias in end-of-life research.
Methods: Within the framework of a European survey on medical end-of-life decisions, a non-response study was conducted among physicians
in Denmark, the Netherlands, Sweden and Switzerland. People were asked about their attitudes and experiences in the area of
medial end-of-life decision. The response rates ranged from 12.8% (Netherlands) to 39.4% (Switzerland). The responders (n
= 5 403) and the non-responders (n = 866) were compared regarding socio-demographic characteristics, experiences with terminal
patients and agreement with attitudes towards “end-of-life decisions”. The reasons for non-participation to the study were
analyzed. 相似文献